Ramachandra S. Hosmane
 |
 |
Ramachandra S. Hosmane | |
|---|---|
| Born | 1944 |
| Nationality | USA |
| Alma mater | University of South Florida; University of Illinois, Urbana-Champaign; Karnatak University |
| Scientific career | |
| Fields | Chemistry |
| Institutions | University of Maryland, Baltimore County |
Ramachandra S. Hosmane (1944-) is a retired Senior Professor of Organic Chemistry at University of Maryland, Baltimore County. Dr. Hosmane has over 150 peer-reviewed research publications in reputed international journals. He has 4 awarded US patents, three of which have been licensed to industries. His contributions to the field of Organic Chemistry and medicinal chemistry are notable. He has trained well over 100 undergraduate students, 30 graduate students, and 20 postdoctoral fellows and visiting scientists in his laboratory. His current research focus is on drug discovery for dual inhibition of HCV and HIV as well as lung, breast, and prostate cancers.
Early life
Mr. Ram Hosmane was born in Gokarna, Uttar Kannada, India and completed high school from Bhadrakali High School, Gokarna. In 1966, he earned B.Sc Chemistry from Karnataka University, Dharwar, followed by M.Sc. degree in Organic Chemistry from the same institution in 1968.
Career
Mr. Hosmane moved to USA in the early 70's to pursue a doctoral degree in organic synthesis and medicinal chemistry at the University of South Florida, where he earned M.S. (1976) and Ph.D. (1978) degrees. After completing his postdoctoral training (1979–82) at the University of Illinois, Urbana-Champaign, Dr. Hosmane joined UMBC as an Asst. Professor in the year 1982 and was promoted to Associate Professor with academic tenure in the year 1986. He was promoted to the rank of full Professor in the year 1994.
His research work has been supported by ~ 50 grants by Federal & State agencies such as the National Institutes of Health and the Maryland Industrial Partnerships (MIPS), and Private Foundations such as the American Heart Association, American Cancer Society, and Petroleum Research Fund as well as a variety of industrial sources. He has contributed significantly to the Development of Organic and Medicinal Chemistry.
Dr. Hosmane was awarded the Presidential Teaching Professorship for years 2009-2012 from UMBC. He was earlier recognized as the Maryland Chemist of the Year from American Chemical Society, Maryland Division in 2002. In 2001, he was awarded Outstanding Educator of the Year Award from Maryland Association for Higher Education (MAHE). Also he was honored as the University Presidential Research Professor for years 1998-2001. In 1996, he was Outstanding Mentor, Project SEED (American Chemical Society). In 1999, he was given honorary faculty membership in Golden Key International Honor Society. He has been a consistent member of the Scientific Review Groups, serving on a wide variety of NIH grant review panels generally referred to as Study Sections. He is also a reviewer for U.S.Food and Drug Administration (FDA)'s intramural scientific programs.
Two major research areas of Dr. Hosmane include blood substitutes based on hemoglobins and the discovery of antiviral and anticancer compounds based on ring-expanded nucleoside structures. The compounds synthesized in his laboratory have shown potent activities against a wide variety of viruses and cancers, including the hepatitis B (HBV) and hepatitis C (HCV) viruses, human immunodeficiency virus (HIV), the West Nile virus (WNV), the Japanese encephalitis virus (JEV), the measles virus, the rhino virus , the Varicella zoster virus (VZV), Epstein-Barr virus, respiratory syncytial virus (RSV), influenza viruses A & B, Herpes Simplex viruses as well as prostate cancer, lung cancer, breast cancer, colon cancer, and leukemia. His current research focus is on drug discovery for dual inhibition of HCV and HIV as well as lung, breast, and prostate cancers.
Dr. Hosmane is a Managing Editor, Frontiers in Bioscience; Current Topics in Medicinal Chemistry; Regional Editor, Molecules. He acted as peer reviewer for PRF, NIH, NSF, American Heart Association, Research Corporation, Guggenheim Foundation; Journals: JACS, JOC, Tet. Lett., J.Het.Chem., J. Med. Chem., Synthesis, Chem. Ber., Liebigs Ann. Chem., Nucleosides & Nucleotides, Nucl. Acids Res., J. Biomol.Struct. Dyn., Tetrahedron, Angewandte Chemie, Eur. J. Org. Chem., Hemoglobin, Bioorg. Med. Chem., Bioorg. Med. Chem. Lett.
He is a member of Sigma Xi; Affiliate IUPAC, Am. Chem. Soc., Chem. Soc.(London), Internat. Soc. Heterocycl. Chem., Internat. Soc. Antiviral Research, and American Assoc. Adv. Science.
Dr. Hosmane is married to Raji. They have one daughter Mala.
Recent References - a few are listed
S. Chakraborty, N. H. Shah, J. C. Fishbein, and R. S. Hosmane, "A Novel Transition State Analogue Inhibitor of Guanase Based on Azepinomycin Ring Structure: Synthesis and Biochemical Assessment of Enzyme Inhibition," Bioorg. Med. Chem. Lett. 2011, 21, 756-759.
A. Kondaskar, S. Kondaskar, R. Kumar, N. Muvarak, R. G. Lapidus, M. Sadowska, M. J. Edelman, G. M. Bol, F. Vesuna, V. Raman, and R. S. Hosmane, "Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System," ACS Med. Chem. Lett. 2011, 2,
H. Cai, T. A. Roach, M. Dabek, K. S. Somerville, S. Acharya, and R. S. Hosmane, "Bis[2-(3-carboxyphenoxy)carbonylethyl]phosphinic Acid (m-BCCEP): A Novel Affinity Cross-Linking Reagent for the b-Cleft Modification of Hemoglobin," Bioconj. Chem. 2010, 21, 1494-1507.
M. Xie, R. K. Ujjinamatada, M. Sadowska, R. G. Lapidus, M. J. Edelman, and R. S. Hosmane, "A Novel, Broad-Spectrum Anticancer Compound Containing the Imidazo[4,5-e][1,3]diazepine Ring System," Bioorg. Med. Chem. Lett. 2010, 20, 4386-4389.
K. Watashi, M. L. Yeung, M. F. Starost, R. S. Hosmane, and K. -T. Jeang, "Identification of Small Molecules that Suppress Micro RNA Function and Reverse Tumorigenesis," J. Biol. Chem. 2010, 285, 24707-24716.
R. S. Hosmane and J. F. Liebman, "Paradoxes and Paradigms: Why is Quinoline Less Basic than Pyridine or Isoquinoline? A Classical Organic Chemical Perspective,” Struct. Chem. 2009, 20, 693-697.
R. S. Hosmane, "Ring-Expanded ("Fat") Purines and Their Nucleoside/Nucleotide Analogues as Broad-Spectrum Therapeutics, ” Progr. Heterocycl. Chem. 2009, 21, 35-68.
R. Kumar, R. K. Ujjinamatada, and R. S. Hosmane ” The First Synthesis of a Novel 5:7:5-Fused Diimidazodiazepine Ring System and Some of Its Chemical Properties, ” Org. Lett. 2008, 10, 4681-4684.
V. S. R. K. Yedavalli, N. Zhang, P. Zhang, H. Cai, M. F. Starost, R. S. Hosmane, and K-T. Jeang, ” Ring-Expanded (REN) Nucleoside Analogues Inhibit RNA Helicase and Intracellular HIV-1 Replication, ” J. Med. Chem. 2008, 51, 5043-5051.
R. K. Ujjinamatada, P. Phatak, A. M. Burger, and R. S. Hosmane, “Inhibition of adenosine deaminase by analogues of adenosine and inosine incorporating a common heterocyclic base, 4(7)-amino-6(5)H-imidazo[4,5-d]pyridazin-7(4)one,” J. Med. Chem. 2008, 51, 694-698.
P. Zhang, N. Zhang, V. Buckwold, R. S. Hosmane, “Chemical and biological effects of substitution of the 2-position of ring-expanded (“fat”) nucleosides containing the imidazo[4,5-e][1,3] diazepine-4,8-dione ring system: The role of electronic and steric factors on glycosidic bond stability and anti-HCV activity,” Bioorg. Med. Chem., 2007, 15, 4933-4945.
R. K. Ujjinamatada, A. Baier, P. Borowski, and R. S. Hosmane, “An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: Synthesis and in vitro screening of 4-carbamoyl-5- (4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)imidazole-1-β-D-ribofuranoside,” Bioorg. Med. Chem. Lett. 2007, 17, 2285-2288.
P. Zhang, N. Zhang, B. E. Korba, and R. S. Hosmane, “Structure-activity relationship studies on anti-HCV activity of ring-expanded (‘fat’) nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system,” Bioorg. Med. Chem. Lett. 2007, 17, 2225-2228.